{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:31:26Z","timestamp":1781649086488,"version":"3.54.5"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints, spine, and peripheral joints. The widespread application of biological agents has led to significant clinical improvements in the management of AS. However, some patients may develop paradoxical immune deviation following treatment with biologics, such as eczematous drug-induced rash, drug-related vasculitis, and inflammatory bowel disease (IBD).In this study, we present a case of a 25-year-old female patient diagnosed with AS who developed secondary loss of response following 6 months of adalimumab (ADA) therapy. After completing ADA washout, she was started on secukinumab (SEC) treatment. Subsequent to the fourth dose of SEC, the patient developed worsening low back pain accompanied by a severe eczematous rash. Treatment was then switched to upadacitinib (UPA). After 6 months of UPA administration, both her AS and drug-induced atopic dermatitis (AD) achieved significant clinical remission.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1737773","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:35:49Z","timestamp":1777613749000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Upadacitinib for atopic dermatitis induced by secukinumab in patients with refractory ankylosing spondylitis:a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Jinxia","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University","place":["Taizhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobiao","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University","place":["Taizhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.77363","article-title":"Paradoxical inflammatory bowel disease induced by golimumab in a patient with ankylosing spondylitis: a case report and systematic review","volume":"17","author":"Alnaqbi","year":"2025","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50726","article-title":"Paradoxical psoriasis and worsening spondylitis due to secukinumab in a patient with ankylosing spondylitis: a case report and literature review","volume":"15","author":"Alnaqbi","year":"2023","journal-title":"Cureus"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15599","article-title":"Review of secukinumab-induced adverse events of special interest and its potential pathogenesis","volume":"35","author":"Liang","year":"2022","journal-title":"Dermatol Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14712598.2019.1554053","article-title":"Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis","volume":"19","author":"Wendling","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3435","article-title":"Cutaneous vasculitis with gut involvement during secukinumab treatment for psoriatic arthritis","volume":"100","author":"Chelli","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/1574886314666190726155147","article-title":"A rare case of drug-induced erectile dysfunction with secukinumab solved after switch to ixekizumab in a psoriatic patient: a case report","volume":"15","author":"Dastoli","year":"2020","journal-title":"Curr Drug Saf"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17779","article-title":"Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition","volume":"181","author":"Napolitano","year":"2019","journal-title":"Br J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2016.2900","article-title":"Drug eruption caused by secukinumab","volume":"27","author":"Shibata","year":"2017","journal-title":"Eur J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1727439","article-title":"Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature","volume":"20","author":"Caldarola","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12751","article-title":"Atopic-like dermatitis after secukinumab injection: a case report","volume":"32","author":"Burlando","year":"2019","journal-title":"Dermatol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.s165605","article-title":"Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date","volume":"12","author":"Galluzzo","year":"2019","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1730326","article-title":"The safety of brodalumab for the treatment of psoriasis","volume":"19","author":"Iznardo","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02732-6","article-title":"Safety of upadacitinib in immune-mediated inflammatory diseases: systematic literature review of indirect and direct treatment comparisons of randomized controlled trials","volume":"41","author":"Mysler","year":"2024","journal-title":"Adv Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"van der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.s430156","article-title":"Secukinumab-induced alopecia areata successfully treated with tofacitinib in a patient with palmoplantar pustulosis","volume":"16","author":"Zhang","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112762","article-title":"Janus kinase inhibitor tofacitinib successfully treated palmoplantar pustulosis after switching from secukinumab: a case report and review of the literature","volume":"139","author":"Fan","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.70305","article-title":"Case report: successful treatment of secukinumab-induced SAPHO syndrome with tofacitinib","volume":"28","author":"Li","year":"2025","journal-title":"Int J Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1737773\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:35:50Z","timestamp":1777613750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1737773\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2026.1737773"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1737773","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"1737773"}}